Stock Market Reviews

JBIO (Jade Biosciences, Inc.) News

Get the latest news, insights, and market updates on JBIO (Jade Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Jade Biosciences to Participate in Upcoming Conferences
  SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference | February 25-26, 2026Presentation: Thursday, February 26 at 1:20 p.m. ET |Track 3TD Cowen 46th Annual Health Care Conference | March 2-4, 202
  Feb 11, 2026 - $JBIO
• H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
  Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically […]
  Jan 19, 2026 - $JBIO
• Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week
  Key Insights Institutions' substantial holdings in Jade Biosciences implies that they have significant influence over...
  Jan 6, 2026 - $JBIO
• Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
  JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027Third development candidate, JADE301, nomin
  Jan 5, 2026 - $JBIO
• Jade Biosciences Announces $45 Million Private Placement
  SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Purs
  Dec 15, 2025 - $JBIO
• Jade Biosciences (JBIO): Analyst Lauds Entry into Market
  Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target. In an investor note, the analyst underlined that there was conviction in JADE101, which […]
  Dec 10, 2025 - $JBIO
• Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
  The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 65% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Dec 4, 2025 - $JBIO
• Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know
  The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 52.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 18, 2025 - $JBIO
• What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
  Jade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Nov 18, 2025 - $JBIO
• Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half of 2026 are anticipated to define dose and dose interval selection for patient trials Unveiled JADE201, a
  Nov 13, 2025 - $JBIO